Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20399875 | 0.92 | S1PR5 (0.46) | S1PR5S1PR1FUCA1BCHEMAOB | |
| SCHEMBL18980644 | 0.87 | L3MBTL1 (0.44) | S1PR5S1PR1FUCA1MEN1LMNA | |
| SCHEMBL19000151 | 0.86 | S1PR5 (0.50) | S1PR5S1PR1FUCA1ACHEMEN1 | |
| SCHEMBL16519954 | 0.79 | L3MBTL1 (0.46) | S1PR5S1PR1BCHEACHEMEN1 | |
| SCHEMBL28662028 | 0.76 | S1PR5 (0.44) | S1PR5S1PR1FUCA1BCHEMAOB | |
| SCHEMBL8487077 | 0.76 | TBXA2R (0.44) | S1PR5S1PR1FUCA1BCHEMAOB | |
| SCHEMBL8497956 | 0.76 | TBXA2R (0.44) | S1PR5S1PR1FUCA1BCHEMAOB | |
| SCHEMBL16499660 | 0.76 | S1PR5 (0.51) | S1PR5S1PR1FUCA1BCHEMEN1 | |
| SCHEMBL8321582 | 0.75 | S1PR5 (0.48) | S1PR5S1PR1FUCA1MEN1LMNA | |
| SCHEMBL5036890 | 0.75 | KMT2A (0.48) | ACHEMEN1LMNAKMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12122766-B2 | 3-azabicyclo[3,1,1]heptane derivative and pharmaceutical composition including same | LG CHEM, LTD. (KR) | 2024-10-22 | — | — | US | disclosed |
| EP-3842423-B1 | 3-AZABICYCLO[3,1,1]HEPTANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | LG CHEMICAL LTD (KR) | 2023-05-17 | — | — | EP | disclosed |
| EP-3842423-B1 | 3-AZABICYCLO[3,1,1]HEPTANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | LG CHEMICAL LTD (KR) | 2023-05-17 | — | — | EP | disclosed |
| US-20220033381-A1 | 3-AZABICYCLO[3,1,1]HEPTANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | LG CHEM, LTD. (KR) | 2022-02-03 | — | — | US | disclosed |
| US-20220033381-A1 | 3-AZABICYCLO[3,1,1]HEPTANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | LG CHEM, LTD. (KR) | 2022-02-03 | — | — | US | disclosed |
| EP-3842423-A1 | 3-AZABICYCLO[3,1,1]HEPTANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | LG Chem, Ltd. (KR) | 2021-06-30 | — | — | EP | disclosed |
| EP-3842423-A1 | 3-AZABICYCLO[3,1,1]HEPTANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | LG Chem, Ltd. (KR) | 2021-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033381-A1 | 3-AZABICYCLO[3,1,1]HEPTANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | KHK, HK1, GCK | S1PR5 1201/4885S1PR1 1298/4885FUCA1 1063/4885 |
| US-12122766-B2 | 3-azabicyclo[3,1,1]heptane derivative and pharmaceutical composition including same | KHK, HK1, GCK | S1PR5 1201/4885S1PR1 1298/4885FUCA1 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.